BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis 2018;5:ofy174. [PMID: 30094293 DOI: 10.1093/ofid/ofy174] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Prowse N, Hayley S. Microglia and BDNF at the crossroads of stressor related disorders: Towards a unique trophic phenotype. Neurosci Biobehav Rev 2021;131:135-63. [PMID: 34537262 DOI: 10.1016/j.neubiorev.2021.09.018] [Reference Citation Analysis]
2 Thomas AM, Beskid NM, Blanchfield JL, Rosado AM, García AJ, Evavold BD, Babensee JE. Localized hydrogel delivery of dendritic cells for attenuation of multiple sclerosis in a murine model. J Biomed Mater Res A 2021;109:1247-55. [PMID: 33040412 DOI: 10.1002/jbm.a.37118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Inshasi JS, Almadani A, Fahad SA, Noori SI, Alsaadi T, Shakra M, Shatila AO, Zein TM, Boshra A. High-efficacy therapies for relapsing-remitting multiple sclerosis: implications for adherence. An expert opinion from the United Arab Emirates. Neurodegener Dis Manag 2020;10:257-66. [PMID: 32438857 DOI: 10.2217/nmt-2020-0016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Otero-Romero S, Rodríguez-García J, Vilella A, Ara JR, Brieva L, Calles C, Carmona O, Casanova V, Costa-Frossard L, Eichau S, García-Merino JA, Garcia-Vidal C, González-Platas M, Llaneza M, Martínez-Ginés M, Meca-Lallana JE, Prieto JM, Rodríguez-Antigüedad A, Tintoré M, Blanco Y, Moral E; en nombre del Grupo de enfermedades desmielizantes de la SEN. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia (Engl Ed) 2021;36:50-60. [PMID: 32561334 DOI: 10.1016/j.nrl.2020.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Signoriello E, Bonavita S, Sinisi L, Russo CV, Maniscalco GT, Casertano S, Saccà F, Lanzillo R, Morra VB, Lus G. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series. Mult Scler Relat Disord 2020;40:101963. [PMID: 31986424 DOI: 10.1016/j.msard.2020.101963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Arrambide G, Iacobaeus E, Amato MP, Derfuss T, Vukusic S, Hemmer B, Brundin L, Tintore M; 2018 ECTRIMS Focused Workshop Group. Aggressive multiple sclerosis (2): Treatment. Mult Scler 2020;:1352458520924595. [PMID: 32530366 DOI: 10.1177/1352458520924595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Martinot M, Abou-Bacar A, Lamothe M, Tebacher MA, Zadeh MM, Dalle F, Favennec L, Costa D, Brunet J, Sellal F. Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review. BMC Infect Dis 2020;20:257. [PMID: 32228484 DOI: 10.1186/s12879-020-04988-7] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Lucchini M, Del Giacomo P, De Arcangelis V, Nociti V, Bianco A, De Fino C, Presicce G, Cicia A, Carlomagno V, Mirabella M. The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre. JPM 2022;12:591. [DOI: 10.3390/jpm12040591] [Reference Citation Analysis]
9 Nast A, Smith C, Spuls P, Avila Valle G, Bata‐csörgö Z, Boonen H, De Jong E, Garcia‐doval I, Gisondi P, Kaur‐knudsen D, Mahil S, Mälkönen T, Maul J, Mburu S, Mrowietz U, Reich K, Remenyik E, Rønholt K, Sator P, Schmitt‐egenolf M, Sikora M, Strömer K, Sundnes O, Trigos D, Van Der Kraaij G, Yawalkar N, Dressler C. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021;35:281-317. [DOI: 10.1111/jdv.16926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Swart ECS, Mager D, Parekh N, Heyman RA, Henderson R, Munshi K, Bridges G, Good CB. Infection incidence and management in multiple sclerosis patients after initiating disease-modifying therapy. Mult Scler Relat Disord 2021;56:103285. [PMID: 34662846 DOI: 10.1016/j.msard.2021.103285] [Reference Citation Analysis]
11 Ng HS, Rosenbult CL, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf 2020;19:1069-94. [PMID: 32799563 DOI: 10.1080/14740338.2020.1807002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
12 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
13 Schweitzer F, Laurent S, Fink GR, Barnett MH, Hartung HP, Warnke C. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. J Neurol 2021;268:2379-89. [PMID: 32036423 DOI: 10.1007/s00415-019-09690-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
14 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Goldschmidt C, McGinley MP. Advances in the Treatment of Multiple Sclerosis. Neurol Clin 2021;39:21-33. [PMID: 33223085 DOI: 10.1016/j.ncl.2020.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Yamout BI, Zakaria M, Inshasi J, Al-Jumah M, Zeineddine M, Dahdaleh M, Bohlega S, Gouider R, Alroughani R. MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis. Mult Scler Relat Disord 2021;56:103225. [PMID: 34479111 DOI: 10.1016/j.msard.2021.103225] [Reference Citation Analysis]
17 Gklinos P, Papadopoulou M, Stanulovic V, Mitsikostas DD, Papadopoulos D. Monoclonal Antibodies as Neurological Therapeutics. Pharmaceuticals (Basel) 2021;14:92. [PMID: 33530460 DOI: 10.3390/ph14020092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zappulo E, Buonomo AR, Saccà F, Russo CV, Scotto R, Scalia G, Nozzolillo A, Lanzillo R, Tosone G, Gentile I. Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. Open Forum Infect Dis 2019;6:ofz445. [PMID: 31723572 DOI: 10.1093/ofid/ofz445] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
19 Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
20 Rastas C, Sirignano D, Barner A, Bruno-murtha LA. Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis. J Neurol 2019;266:2867-8. [DOI: 10.1007/s00415-019-09483-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
21 Smets I, Giovannoni G. Derisking CD20-therapies for long-term use. Mult Scler Relat Disord 2021;57:103418. [PMID: 34902761 DOI: 10.1016/j.msard.2021.103418] [Reference Citation Analysis]
22 Miyasaka A, Sato S, Masuda T, Takikawa Y. A 55-Year-Old Japanese Man with Multiple Sclerosis Diagnosed with Disseminated Tuberculosis Identified by Liver Function Abnormalities: A Case Report. Am J Case Rep 2021;22:e931369. [PMID: 34404756 DOI: 10.12659/AJCR.931369] [Reference Citation Analysis]
23 Laundy N, Colley S, Fawcett J, Ryder L, Vedio A, Cohen D, Collini P. Assessment of latent tuberculosis infection pre-immunomodulatory therapy; 5 year experience in a UK centre. Clinical Infection in Practice 2022;13:100136. [DOI: 10.1016/j.clinpr.2022.100136] [Reference Citation Analysis]
24 Waubant E, Giovannoni G, Hawkes C, Levy M. Vaccines and disease-modifying treatments. Multiple Sclerosis and Related Disorders 2018;26:A1-2. [DOI: 10.1016/j.msard.2018.10.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Multani A, Ho DY. JC Polyomavirus Infection Potentiated by Biologics. Infect Dis Clin North Am 2020;34:359-88. [PMID: 32444013 DOI: 10.1016/j.idc.2020.02.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
26 Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F. [Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany]. Nervenarzt 2019;90:1245-53. [PMID: 31297574 DOI: 10.1007/s00115-019-0760-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Laroni A, Schiavetti I, Sormani MP, Uccelli A. COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments. Mult Scler 2020;:1352458520971817. [PMID: 33205695 DOI: 10.1177/1352458520971817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
28 Moiola L, Rommer PS, Zettl UK. Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis. Curr Opin Neurol 2020;33:286-94. [PMID: 32374570 DOI: 10.1097/WCO.0000000000000824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
29 Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019;12:1756286419836571. [PMID: 30967901 DOI: 10.1177/1756286419836571] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
30 Ciotti JR, Valtcheva MV, Cross AH. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord 2020;45:102439. [PMID: 32769063 DOI: 10.1016/j.msard.2020.102439] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
31 Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020;39:102073. [PMID: 32334820 DOI: 10.1016/j.msard.2020.102073] [Cited by in Crossref: 95] [Cited by in F6Publishing: 92] [Article Influence: 47.5] [Reference Citation Analysis]
32 Rivera-Izquierdo M, Valero-Ubierna MDC, Nieto-Gómez P, Martínez-Bellón MD, Fernández-Martínez NF, Barranco-Quintana JL. Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Rev Vaccines 2020;19:727-44. [PMID: 32702246 DOI: 10.1080/14760584.2020.1800462] [Reference Citation Analysis]
33 Chisari CG, Toscano S, D’amico E, Lo Fermo S, Zanghì A, Arena S, Zappia M, Patti F. An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 2019;18:925-48. [DOI: 10.1080/14740338.2019.1658741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
34 Toscano S, Chisari CG, Patti F. Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurol Ther 2021;10:627-49. [PMID: 34625925 DOI: 10.1007/s40120-021-00288-7] [Reference Citation Analysis]
35 Miauton A, Tan R, Pantazou V, Du Pasquier R, Genton B. Vaccine-associated measles in a patient treated with natalizumab: a case report. BMC Infect Dis 2020;20:753. [PMID: 33054715 DOI: 10.1186/s12879-020-05475-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Reyes S, Cunningham AL, Kalincik T, Havrdová EK, Isobe N, Pakpoor J, Airas L, Bunyan RF, van der Walt A, Oh J, Mathews J, Mateen FJ, Giovannoni G. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. J Neuroimmunol 2021;357:577627. [PMID: 34139567 DOI: 10.1016/j.jneuroim.2021.577627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH. COVID-19 Among Patients With Multiple Sclerosis: A Systematic Review. Neurol Neuroimmunol Neuroinflamm 2021;8:e1001. [PMID: 34016734 DOI: 10.1212/NXI.0000000000001001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
38 Riccardo BA, Giulio V, Massimiliano C, Giovanna L, Valentina T, Paola C, Teresa MG, Diana F, Viviana N, Marta R, Chiara BM, Damiano P, Alberto G, Pietro A, Federica P, Massimiliano DF, Cinzia C, Emanuela Z, Riccardo S, Ivan G, Antonio S, Martina P, Marcello A, Vincenzo BM, Claudio S, Claudio G, Eleonora C, Marcello M, Roberta L; Raising Italian Researchers in Multiple Sclerosis (RIREMS) study group. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. J Neurol 2022. [PMID: 35165767 DOI: 10.1007/s00415-022-11009-x] [Reference Citation Analysis]
39 Lima MR, Farias LABG, da Ponte MF, de Arruda Furtado LET. Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis. Eur J Case Rep Intern Med 2019;6:001046. [PMID: 30931272 DOI: 10.12890/2019_001046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Solmaz I, Anlar B. Immunization in multiple sclerosis and other childhood immune-mediated disorders of the central nervous system: A review of the literature. Eur J Paediatr Neurol 2021;33:125-34. [PMID: 34214824 DOI: 10.1016/j.ejpn.2021.06.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Nicholas JA, Gudesblatt M, Garabedian M, Belviso N, Shen C, Geremakis C, Shankar SL, Mendoza JP, Lewin JB. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103921] [Reference Citation Analysis]
42 Schmierer K, Campion T, Sinclair A, van Hecke W, Matthews PM, Wattjes MP. Towards a standard MRI protocol for multiple sclerosis across the UK. Br J Radiol 2019;92:20180926. [PMID: 30994035 DOI: 10.1259/bjr.20180926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
43 Bortolotti D, Gentili V, Bortoluzzi A, Govoni M, Schiuma G, Beltrami S, Rizzo S, Baldi E, Caselli E, Pugliatti M, Castellazzi M, Fernández M, Fainardi E, Rizzo R. Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity. Microorganisms 2022;10:494. [DOI: 10.3390/microorganisms10030494] [Reference Citation Analysis]
44 Graf J, Albrecht P, Goebels N, Aktas O, Hartung HP. [Ocrelizumab for treatment of multiple sclerosis]. Nervenarzt 2020;91:722-34. [PMID: 32524163 DOI: 10.1007/s00115-020-00937-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 AlSharoqi IA, Aljumah M, Bohlega S, Boz C, Daif A, El-Koussa S, Inshasi J, Kurtuncu M, Müller T, Retief C, Sahraian MA, Shaygannejad V, Slassi I, Taha K, Zakaria M, Sørensen PS. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. Neurol Ther 2020;9:55-66. [PMID: 32297127 DOI: 10.1007/s40120-020-00187-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Papeix C, Donze C, Lebrun-Frénay C; French Group for Recommendations in Multiple Sclerosis (France4MS), the Société Francophone de la Sclérose En Plaques (SFSEP)., Co-Chairs., Group of evaluators Coordinators., Readers., Cotator., Expert readers (voters). Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Rev Neurol (Paris) 2021:S0035-3787(21)00602-0. [PMID: 34303537 DOI: 10.1016/j.neurol.2021.04.011] [Reference Citation Analysis]
47 Onorato L, Pisaturo M, Camaioni C, Grimaldi P, Codella AV, Calò F, Coppola N. Risk and Prevention of Hepatitis B Virus Reactivation during Immunosuppression for Non-Oncological Diseases. J Clin Med 2021;10:5201. [PMID: 34768721 DOI: 10.3390/jcm10215201] [Reference Citation Analysis]
48 Gomez-Larrauri A, Das Adhikari U, Aramburu-Nuñez M, Custodia A, Ouro A. Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer. Medicina (Kaunas) 2021;57:729. [PMID: 34357010 DOI: 10.3390/medicina57070729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Dantas LA, Pereira MS, Gauza AM, Schulz MEB, Silva GFD, Martin MEM, Medeiros Junior WLG, Gonçalves MVM. Latent tuberculosis infection reactivation in patients with multiple sclerosis in use of disease-modifying therapies: A systematic review. Mult Scler Relat Disord 2021;55:103184. [PMID: 34384990 DOI: 10.1016/j.msard.2021.103184] [Reference Citation Analysis]
50 Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost 2022;28:107602962110566. [DOI: 10.1177/10760296211056648] [Reference Citation Analysis]
51 Bavaro DF, Fiordelisi D, Angarano G, Monno L, Saracino A. Targeted therapies for autoimmune/idiopathic nonmalignant diseases: risk and management of opportunistic infections. Expert Opin Drug Saf 2020;19:817-42. [PMID: 32394759 DOI: 10.1080/14740338.2020.1767585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
52 ApÓstolos-Pereira SL, Silva GD, Disserol CCD, Feo LB, Matos AMB, Schoeps VA, Gomes ABAGR, Boaventura M, Mendes MF, Callegaro D. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach. Arq Neuropsiquiatr 2020;78:430-9. [PMID: 32609290 DOI: 10.1590/0004-282X20200056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli SG, Merluzzo C, Baione V, Mazzochi L, Taglietti A, Pauri F, Frontoni M, Altieri M, Gaeta A, Antonelli G, Conte A, Mastroianni CM, Ciardi MR. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. Mult Scler J Exp Transl Clin 2022;8:20552173211065731. [PMID: 35003758 DOI: 10.1177/20552173211065731] [Reference Citation Analysis]
54 Coyle PK, Gocke A, Vignos M, Newsome SD. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Adv Ther 2021;38:3550-88. [PMID: 34075554 DOI: 10.1007/s12325-021-01761-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
55 Riva A, Barcella V, Benatti SV, Capobianco M, Capra R, Cinque P, Comi G, Fasolo MM, Franzetti F, Galli M, Gerevini S, Meroni L, Origoni M, Prosperini L, Puoti M, Scarpazza C, Tortorella C, Zaffaroni M, Moiola L. Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Mult Scler 2021;27:347-59. [PMID: 32940128 DOI: 10.1177/1352458520952310] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
56 Ferro D, Prista-Leão B, Costa A, Silva-Pinto A, Abreu C, Sá MJ. Infectious Risk Mitigation in Patients with Multiple Sclerosis under Disease-Modifying Therapies - the Experience of a Collaborative Neurology-Infectious Diseases Approach. J Cent Nerv Syst Dis 2021;13:11795735211042188. [PMID: 34526834 DOI: 10.1177/11795735211042188] [Reference Citation Analysis]
57 Baldassari LE, Feng J, Macaron G, Planchon SM, Alshehri E, Moss BP, Ontaneda D, Willis MA. Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting. Mult Scler J Exp Transl Clin 2019;5:2055217319875467. [PMID: 31588362 DOI: 10.1177/2055217319875467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
58 Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2021;21:36. [PMID: 34009478 DOI: 10.1007/s11910-021-01117-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Faustino P, Coutinho M, Leitão L, Capela C, Brum M, Parra J, Sequeira J, Barros A, Araújo C, Sousa A, Ladeira F. Seroconversion rate following HBV vaccination in clinical practice: The role of age and DMT treatment. Mult Scler Relat Disord 2021;50:102859. [PMID: 33652232 DOI: 10.1016/j.msard.2021.102859] [Reference Citation Analysis]
60 Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs 2021;35:861-80. [PMID: 34319570 DOI: 10.1007/s40263-021-00842-9] [Reference Citation Analysis]
61 Castelo-Branco A, Chiesa F, Conte S, Bengtsson C, Lee S, Minton N, Niemcryk S, Lindholm A, Rosenlund M, Piehl F, Montgomery S. Infections in patients with multiple sclerosis: A national cohort study in Sweden. Mult Scler Relat Disord 2020;45:102420. [PMID: 32736217 DOI: 10.1016/j.msard.2020.102420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
62 Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J, Marta M, Turner B, Gnanapavan S, Dobson R, Schmierer K, Giovannoni G. Protecting people with multiple sclerosis through vaccination. Pract Neurol 2020;20:435.1-445. [DOI: 10.1136/practneurol-2020-002527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
63 Sirbu CA, Dantes E, Plesa CF, Docu Axelerad A, Ghinescu MC. Active Pulmonary Tuberculosis Triggered by Interferon Beta-1b Therapy of Multiple Sclerosis: Four Case Reports and a Literature Review. Medicina (Kaunas) 2020;56:E202. [PMID: 32344653 DOI: 10.3390/medicina56040202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
64 Capasso N, Palladino R, Montella E, Pennino F, Lanzillo R, Carotenuto A, Petracca M, Iodice R, Iovino A, Aruta F, Pastore V, Buonomo AR, Zappulo E, Gentile I, Triassi M, Brescia Morra V, Moccia M. Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. J Clin Med 2020;9:E4066. [PMID: 33339402 DOI: 10.3390/jcm9124066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
65 Sipilä JOT, Soilu-Hänninen M, Rautava P, Kytö V. Progressive multifocal leukoencephalopathy in Finland: a cross-sectional registry study. J Neurol 2019;266:515-21. [PMID: 30612143 DOI: 10.1007/s00415-018-09167-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
66 Moiola L, Barcella V, Benatti S, Capobianco M, Capra R, Cinque P, Comi G, Fasolo MM, Franzetti F, Galli M, Gerevini S, Meroni L, Origoni M, Prosperini L, Puoti M, Scarpazza C, Tortorella C, Zaffaroni M, Riva A. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. Mult Scler 2021;27:331-46. [PMID: 32940121 DOI: 10.1177/1352458520952311] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]